SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2018

TRINITY BIOTECH PLC
(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow
Ireland
 (Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):______

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):______

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes ☐          No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______

 
 
Press Release dated November 29, 2018
 
Contact:
Trinity Biotech plc
Lytham Partners LLC
 
Kevin Tansley
Joe Diaz, Joe Dorame & Robert Blum
 
(353)-1-2769800
602-889-9700
 
E-mail: kevin.tansley@trinitybiotech.com
  
 
CEO Ronan O’Caoimh Increases Shareholding in Trinity Biotech

DUBLIN, Ireland (November 29, 2018)…. Trinity Biotech plc (Nasdaq: TRIB), today announced that Ronan O’Caoimh, CEO of Trinity Biotech, has increased his shareholding in Trinity Biotech by the acquisition of 425,000 ADRs. As a result of this transaction, Mr. O’Caoimh’s shareholding in Trinity Biotech has increased from 1,339,374 ADRs to 1,764,374 ADRs which represents 8.4% of the company’s share capital excluding the impact of share options. The increase in shareholding was due to shares purchased in the open market. This was in addition to the purchase of 430,000 ADR’s by Ronan O’Caoimh which was announced in June 2018.
 
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
TRINITY BIOTECH PLC
(Registrant)
 
By: /s/ Kevin Tansley
     Kevin Tansley
     Chief Financial Officer
 
Date:  29 November 2018